11:07 AM EDT, 09/13/2024 (MT Newswires) -- C4 Therapeutics ( CCCC ) said Friday that initial data from an ongoing phase 1 clinical trial of small molecule degrader candidate CFT1946 targeting BRAF V600 mutations in solid tumors is well tolerated at all doses and there were no dose-limiting toxicities.

Mild to bothersome adverse events occurred in over 10% of patients but no patients discontinued treatment or experienced interruptions, according to the company.

C4 said out of 27 patients who could be evaluated for antitumor activity at the cutoff date, 16 showed a reduction in target metastatic lesions and two had a confirmed partial response.

The company said the trial is advancing with ongoing dose escalation in monotherapy and combination therapies across multiple cancer types, with key data from these groups expected in 2025, while a new trametinib combination in melanoma will be launched in late 2024.

Shares of the company were up 7.6% in recent trading.

Price: 6.90, Change: +0.49, Percent Change: +7.64